 Affimed NV NASDAQ: AFMD has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer cbNK cells pre-complexed with Affimeds innate cell engager ICE AFM13 CD16ACD30. The trial evaluates the pre-complexing of AFM13 with cbNK cells followed by three weekly infusions of AFM13 monotherapy in adult patients with recurrentrefractory CD30-positive lymphomas. 